News

Explore This Section

BIOVIA Accelerates Development of Covid-19 Treatments

“By providing academic researchers access to BIOVIA Discovery Studio licenses, we’re helping to multiply the talent pool at work on the COVID-19 challenge, and we’re helping to shorten the process from concept to cure,” said Tien Luu, Ph.D., senior technical specialist, life sciences portfolio of BIOVIA.  “Discovery Studio can greatly accelerate every step of the research process, from the ability to identify the most promising target molecules for study to the ability to predict the toxicity of those target molecules.

COVID-19 Funding Opportunities and Resources

COVID-19 FUNDING & RESOURCES

We know this is a challenging time for researchers and entrepreneurs. UCLA TDG is committed to helping you navigate these uncertain times.

We have compiled the latest updates about resources – including funding opportunities, discounted services for startups, business relief programs and company preparedness resources, and webinars – that are available to help innovators, entrepreneurs, and startups address the challenges you may be facing during the COVID-19 pandemic.

UCLA TDG STAFF WORKING REMOTE

                   IMPORTANT ANNOUNCEMENT REGARDING

                   UCLA TECHNOLOGY DEVELOPMENT GROUP 

 

UCLA TDG is exercising caution with regard to novel coronavirus (COVID-19). Accordingly, most of our staff are working remotely. Remote TDG staff will use the Zoom Meeting client to conduct meetings, and are available via phone and email during regular business hours.

UCLA Researchers Currently Developing Rapid COVID-19 Testing

UCLA researchers in the Department of Molecular and Medical Pharmacology have discovered high affinity binding affibodies to COVID-19’s nucleocapsid protein that provide the basis for an ELISA-based diagnostic platform. The researchers are currently developing affibody-coated test strips for saliva detection of COVID-19 in high population settings or at home testing. More information can be found here